PD-L1 Nanobody scintigraphy for immune landscape imaging of the thyroid: first-in-human application and histopathologic correlation

PD-L1 Nanobody scintigraphy for immune landscape imaging of the thyroid: first-in-human application and histopathologic correlation - ThyroMap1

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00039812

Enrollment

Registered

2026-04-14

Start date

2026-04-10

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

E04.2 E04.1

Interventions

Group 1: Patients who were examined with ThyroMap1.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Patients who have undergone thyroid scintigraphy (including PD-L1 nanobody scintigraphy) - Available histopathological examination following thyroid surgery - Complete clinical and imaging datasets

Exclusion criteria

Exclusion criteria: - Incomplete datasets - Lack of histopathological correlation

Design outcomes

Primary

Measure	Time frame
Correlation of imaging-determined PD-L1 expression with immunohistochemically determined PD-L1 expression in the resected specimen.	—

Secondary

Measure	Time frame
Qualitative and semi-quantitative evaluation of tracer uptake Relationship with clinical and laboratory parameters Assessment of the diagnostic value of the method	—

Countries

Germany

Contacts

Public ContactBarbara Kreppel

Klinik und Poliklinik für Nuklearmedizin, Uniklinik Bonn

barbara.kreppel@ukbonn.de0204922828715181

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 29, 2026